Sign in or create an account to add this stock to your watchlist.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000
Debt
Debt-to-Equity Ratio0.87
Current Ratio6.55
Quick Ratio6.41
Price-To-Earnings
Trailing P/E Ratio-5.03
Forward P/E Ratio-5.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.11 million
Price / Sales59.98
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book6.80
Profitability
EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net Margins-706.11%
Return on Equity-108.95%
Return on Assets-64.23%
Miscellaneous
Employees561
Outstanding Shares45,460,000
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health (NASDAQ:RDUS) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, topping analysts' consensus estimates of ($1.46) by $0.09. The biopharmaceutical company earned $14.50 million during the quarter, compared to analysts' expectations of $13.80 million. Radius Health had a negative return on equity of 108.95% and a negative net margin of 706.11%. During the same period in the prior year, the business posted ($1.32) EPS. View Radius Health's Earnings History.
What price target have analysts set for RDUS?
9 Wall Street analysts have issued twelve-month price targets for Radius Health's stock. Their forecasts range from $31.00 to $85.00. On average, they anticipate Radius Health's stock price to reach $54.25 in the next twelve months. View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)
- 2. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Forteo and Prolia. Further, the company suffered a setback when the CHMP issued a negative trend vote on the benefit-risk balance for the MAA for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The delay in getting approval in Europe is disappointing given the market potential. The company’s shares have underperformed the industry in the last three months. Meanwhile, estimates are stable ahead of the first-quarter results (scheduled on May 8)." (5/2/2018)
- 3. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Catalent (CTLT), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), FibroGen (FGEN), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE) and Amicus Therapeutics (FOLD).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Dr. Gregory Williams Ph.D., MBA, Chief Devel. Officer (Age 59)
- Dr. Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 64)
- Mr. Brian Nicholas Harvey, Advisor (Age 57)
- Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
- Dr. Stavros C. Manolagas M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board
Has Radius Health been receiving favorable news coverage?
News stories about RDUS stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Radius Health earned a media sentiment score of 0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Radius Health's major shareholders?
Radius Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BB Biotech AG (12.94%), Farallon Capital Management LLC (8.99%), MPM Asset Management LLC (8.84%), Point72 Asset Management L.P. (4.05%), OppenheimerFunds Inc. (1.84%) and Franklin Resources Inc. (0.82%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.
Which major investors are selling Radius Health stock?
RDUS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., DekaBank Deutsche Girozentrale, Franklin Resources Inc., Sei Investments Co., Russell Investments Group Ltd., Teacher Retirement System of Texas and Guggenheim Capital LLC. View Insider Buying and Selling for Radius Health.
Which major investors are buying Radius Health stock?
RDUS stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., BB Biotech AG, Farallon Capital Management LLC, Eversept Partners LLC, MPM Asset Management LLC, Spark Investment Management LLC, UBS Group AG and Candriam Luxembourg S.C.A.. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $29.17.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.31 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Radius Health (NASDAQ:RDUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Radius Health in the last 12 months. Their average twelve-month price target is $54.25, suggesting that the stock has a possible upside of 85.98%. The high price target for RDUS is $85.00 and the low price target for RDUS is $31.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.64 | 2.60 | 2.63 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $54.25 | $52.10 | $51.7778 | $51.00 |
| Price Target Upside: | 85.98% upside | 51.59% upside | 47.26% upside | 76.10% upside |
Radius Health (NASDAQ:RDUS) Consensus Price Target History
Radius Health (NASDAQ:RDUS) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Radius Health (NASDAQ:RDUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.42%
Radius Health (NASDAQ RDUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2018 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $28.91 | $1,156,400.00 | 6,150,913 |  |
| 5/21/2018 | Growth N V Biotech | Major Shareholder | Buy | 60,000 | $29.27 | $1,756,200.00 | 6,110,913 | |
| 4/19/2018 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $33.80 | $1,352,000.00 | 6,050,913 | |
| 4/5/2018 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.58 | $1,829,000.00 | 5,903,799 | |
| 3/2/2018 | Growth N V Biotech | Major Shareholder | Buy | 80,000 | $32.52 | $2,601,600.00 | 5,853,799 | |
| 2/9/2018 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $34.38 | $2,578,500.00 | 5,773,799 | |
| 11/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $26.25 | $1,312,500.00 | 5,698,799 | |
| 11/10/2017 | Brent Hatzis-Schoch | VP | Buy | 1,778 | $28.09 | $49,944.02 | 2,278 | |
| 11/7/2017 | Jesper Hoiland | Insider | Buy | 6,800 | $29.04 | $197,472.00 | 12,900 | |
| 11/3/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $29.15 | $1,457,500.00 | 5,648,799 | |
| 10/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $32.85 | $1,642,500.00 | 5,548,799 | |
| 9/15/2017 | Jesper Hoiland | Insider | Buy | 6,100 | $32.72 | $199,592.00 | 6,100 | |
| 9/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $33.45 | $5,017,500.00 | 5,448,799 | |
| 9/14/2017 | Jose Carmona | CFO | Buy | 3,000 | $32.83 | $98,490.00 | 3,000 | |
| 9/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.42 | $1,771,000.00 | 5,348,799 | |
| 9/5/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.75 | $1,837,500.00 | 5,298,799 | |
| 8/16/2017 | Growth N V Biotech | Major Shareholder | Buy | 60,000 | $35.98 | $2,158,800.00 | 5,248,799 | |
| 8/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $34.97 | $5,245,500.00 | 5,113,799 | |
| 5/30/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $34.21 | $1,368,400.00 | 5,038,799 | |
| 5/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $36.25 | $1,450,000.00 | 4,998,799 | |
| 5/18/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $34.41 | $1,720,500.00 | 4,958,799 | |
| 5/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $33.44 | $1,170,400.00 | 4,890,799 | |
| 5/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 15,000 | $34.00 | $510,000.00 | 4,873,799 | |
| 5/9/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.93 | $1,796,500.00 | 4,858,799 | |
| 5/8/2017 | Growth N V Biotech | Major Shareholder | Buy | 43,400 | $35.57 | $1,543,738.00 | 4,785,999 | |
| 5/2/2017 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $33.91 | $2,543,250.00 | 4,765,399 | |
| 5/1/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $35.39 | $5,308,500.00 | 4,690,399 | |
| 3/21/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.83 | $1,791,500.00 | 4,540,399 | |
| 3/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 30,000 | $38.41 | $1,152,300.00 | 4,490,399 | |
| 3/15/2017 | Growth N V Biotech | Major Shareholder | Buy | 61,721 | $39.97 | $2,466,988.37 | 4,415,930 | |
| 3/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 38,279 | $39.17 | $1,499,388.43 | 4,398,678 | |
| 1/22/2016 | Growth N V Biotech | Major Shareholder | Buy | 38,259 | $31.67 | $1,211,662.53 | 4,360,399 | |
| 1/13/2016 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $39.90 | $1,995,000.00 | 4,322,140 | |
| 11/12/2015 | Gary Hattersley | insider | Sell | 5,683 | $75.00 | $426,225.00 | | |
| 11/3/2015 | Gary Hattersley | insider | Sell | 13,333 | $70.00 | $933,310.00 | | |
| 10/23/2015 | Gary Hattersley | insider | Sell | 11,302 | $65.00 | $734,630.00 | | |
| 10/21/2015 | Gary Hattersley | insider | Sell | 1,501 | $65.36 | $98,105.36 | | |
| 10/21/2015 | Rob Ward | CEO | Sell | 50,000 | $61.99 | $3,099,500.00 | | |
| 8/21/2015 | Growth N. V. Biotech | major shareholder | Buy | 100,000 | $64.00 | $6,400,000.00 | 4,272,140 | |
| 8/17/2015 | Kurt Graves | Director | Sell | 22,694 | $70.00 | $1,588,580.00 | | |
| 7/6/2015 | Kurt Graves | Director | Sell | 25,000 | $69.48 | $1,737,000.00 | | |
| 6/18/2015 | Kurt Graves | Director | Sell | 25,000 | $55.05 | $1,376,250.00 | | |
| 5/1/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.46 | $1,823,000.00 | | |
| 4/29/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.23 | $1,811,500.00 | | |
| 4/28/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.59 | $1,829,500.00 | | |
| 4/27/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $38.38 | $1,919,000.00 | | |
| 3/6/2015 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $47.08 | $3,531,000.00 | | |
| 2/25/2015 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $45.74 | $1,600,900.00 | | |
| 6/11/2014 | Morana Jovan-Embiricos | Director | Buy | 587,500 | $8.00 | $4,700,000.00 | | |
| 6/6/2014 | Growth N V Biotech | Major Shareholder | Buy | 1,000,000 | $8.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) News Headlines
| Source: |
|
Radius Health (NASDAQ:RDUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement
Radius Health (NASDAQ RDUS) Stock Chart for Saturday, May, 26, 2018
Loading chart…
